Draupnir Bio (private company)

See something wrong or missing? Let us know
Offices:Aarhus
Registration number:38546880
Business model:B2B

Draupnir Bio was set out to develop a new type of cholesterol-lowering medicine and developed a platform for exploring the glycome to develop novel therapeutics. The platform is based on array technology, protein chemistry and advanced carbohydrate chemistry.

Investors: we tracked 3 investors

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

values in USD

Investments 33.21M


You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Companies with similar profile to Draupnir Bio

Name Criteria
Denmark AFYX Therapeutics
63%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • At least one vc investor: Novo Seeds
  • Total raised in a similar range: 10M+ USD
Denmark Galecto Biotech
63%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • At least one vc investor: Novo Seeds
  • Total raised in a similar range: 10M+ USD
Denmark MinervaX
63%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • At least one vc investor: Novo Seeds
  • Total raised in a similar range: 10M+ USD
Denmark NMD Pharma
63%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • At least one vc investor: INKEF Capital, Novo Seeds
  • Total raised in a similar range: 10M+ USD
Netherlands Salvia BioElectronics
63%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • At least one vc investor: INKEF Capital
  • Total raised in a similar range: 10M+ USD
Switzerland Synendos Therapeutics
63%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • At least one vc investor: High-Tech Gründerfonds
  • Total raised in a similar range: 10M+ USD
Germany Tubulis
63%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • At least one vc investor: High-Tech Gründerfonds
  • Total raised in a similar range: 10M+ USD
Denmark Antag Therapeutics
53%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • At least one vc investor: Novo Seeds
Denmark Biograil
53%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • At least one vc investor: High-Tech Gründerfonds
Denmark Hoba Therapeutics
53%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • At least one vc investor: Novo Seeds
Top